These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9527775)

  • 1. Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
    Noormohamed FH; Youle MS; Higgs CJ; Martin-Munley S; Gazzard BG; Lant AF
    Antimicrob Agents Chemother; 1998 Feb; 42(2):293-7. PubMed ID: 9527775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
    Noormohamed FH; Youle MS; Higgs CJ; Gazzard BG; Lant AF
    Br J Clin Pharmacol; 1997 Jan; 43(1):112-5. PubMed ID: 9056062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
    Barditch-Crovo PA; Petty BG; Gambertoglio J; Nerhood LJ; Kuwahara S; Hafner R; Lietman PS; Kornhauser DM
    Antiviral Res; 1998 Jun; 38(3):209-12. PubMed ID: 9754889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
    Taburet AM; Katlama C; Blanshard C; Zorza G; Gazzard D; Dohin E; Gazzard BG; Frostegard C; Singlas E
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1821-4. PubMed ID: 1329628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
    Dieterich DT; Poles MA; Lew EA; Martin-Munley S; Johnson J; Nix D; Faust MJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1226-30. PubMed ID: 9174175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
    Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
    Aweeka FT; Gambertoglio JG; van der Horst C; Raasch R; Jacobson MA
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1773-8. PubMed ID: 1416864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis.
    Castelli F; Tomasoni L; Zeroli C; Suter F; Trespi G; Carosi G; Hedman A
    Eur J Clin Pharmacol; 1997; 52(5):397-401. PubMed ID: 9272411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
    Aweeka F; Gambertoglio J; Mills J; Jacobson MA
    Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
    Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
    Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
    Balfour HH; Fletcher CV; Erice A; Henry WK; Acosta EP; Smith SA; Holm MA; Boivin G; Shepp DH; Crumpacker CS; Eaton CA; Martin-Munley SS
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2721-6. PubMed ID: 9124829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
    Aweeka FT; Brody SR; Jacobson M; Botwin K; Martin-Munley S
    Clin Ther; 1998; 20(2):232-43. PubMed ID: 9589815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
    Cundy KC; Barditch-Crovo P; Walker RE; Collier AC; Ebeling D; Toole J; Jaffe HS
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2401-5. PubMed ID: 8585716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
    Drusano GL; Aweeka F; Gambertoglio J; Jacobson M; Polis M; Lane HC; Eaton C; Martin-Munley S
    AIDS; 1996 Sep; 10(10):1113-9. PubMed ID: 8874628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
    Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
    Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients.
    Noormohamed FH; Youle MS; Tang B; Martin-Munley S; Gazzard BG; Lant AF
    Antivir Ther; 1996 Aug; 1(3):172-9. PubMed ID: 11322251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
    Cheung TW; Jayaweera DT; Pearce D; Benson P; Nahass R; Olson C; Wool GM
    Int J STD AIDS; 2000 Oct; 11(10):640-7. PubMed ID: 11057934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
    Jung D; Dorr A
    J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
    Groll AH; Wood L; Roden M; Mickiene D; Chiou CC; Townley E; Dad L; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.